Pfizer Breakthrough Growth Initiative is set to allocate as much as $500m to publicly listed clinical-stage life science technology developers.

MassMutual Ventures now has $450m under management across five funds, with its third main fund to invest in North America, Europe and Israel.

Bigfoot Medical, which is developing smart pens for diabetes management, closed an Abbott-led series C round after securing $45m in the first tranche in January.

Fosun and Varian Medical Systems returned to help medical imaging platform developer Arterys increase its total funding to $70m.

Celgene and BMS-backed cancer therapy developer Repare Therapeutics has filed to go public after raising more than $165m in equity financing.

Ping An Global Voyager Fund has led a $35.4m series C round for the dental aligner producer that will drive continued expansion efforts across Europe.

Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance and Ascension Ventures all took part in the cancer data provider's latest round.

Illumina, General Atlantic and Viking Global have supplied $70m for Ginkgo Bioworks, an MIT spinout that has now raised more than $789m altogether.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Q32 Bio has launched with $46m from investors including University of Colorado to target autoimmune and inflammatory diseases.